Hu Maolin, Lai Shicong, Zhang Yaoguang, Liu Ming, Wang Jianye
Peking University Fifth School of Clinical Medicine, Beijing, China.
Department of Urology, Beijing Hospital, National Center of Gerontology, Beijing, China.
Urol Int. 2019;103(3):337-343. doi: 10.1159/000501529. Epub 2019 Jul 30.
To evaluate the intervention effect of sacral neuromodulation (SNM) in the treatment of lower urinary tract dysfunction after spinal cord injury (SCI).
We selected relevant studies published between January 1, 1971 and November 15, 2018 by searching the PubMed, EMBASE, Cochrane databases. The outcome was assessed as follows: patients who had at least 50% improvement in bladder diary variables (number of leakages, pad use, number of voids, number of catheterizations, and so on). All analyses were performed with R software (version 3.5.1). We used Cochran's Q test and I2 statistics to evaluate the heterogeneity.
A total of 8 articles met all inclusion criteria for the systematic review. According to the Oxford Centre for Evidence-Based Medicine hierarchy, the evidence levels ranged from 2b to 4. During the test phase of SNM, we considered 108 patients. During the test phase, the merged success rate was 45% (95% CI 36-55%, p = 0.23, I2 = 31%). Overall, 99 patients were considered during the permanent implantation phase of SNM; the mean follow-up time ranged from 8.4 to 61.3 months, and the merged success rate of the permanent SNM phase was 75% (95% CI 64-83%, p = 0.46, I2 = 0%). All the reported adverse events were resolved.
Based on current evidence, the success rate of the test phase of SNM for LTUD in SCI patients was low, but in the permanent phase, the success rate of SNM was optimistic. In the future, well-designed randomized controlled trial with adequate sample sizes and power are necessary to validate the efficacy and safety of SNM.
评估骶神经调节(SNM)对脊髓损伤(SCI)后下尿路功能障碍的干预效果。
通过检索PubMed、EMBASE、Cochrane数据库,选取1971年1月1日至2018年11月15日期间发表的相关研究。结果评估如下:膀胱日记变量(漏尿次数、尿垫使用情况、排尿次数、导尿次数等)至少改善50%的患者。所有分析均使用R软件(版本3.5.1)进行。我们使用 Cochr an Q检验和I²统计量评估异质性。
共有8篇文章符合系统评价的所有纳入标准。根据牛津循证医学中心的分级,证据水平从2b到4级不等。在SNM的测试阶段,我们纳入了108例患者。在测试阶段,合并成功率为45%(95%CI 36 - 55%,p = 0.23,I² = 31%)。总体而言,在SNM的永久植入阶段纳入了99例患者;平均随访时间为8.4至61.3个月,永久SNM阶段的合并成功率为75%(95%CI 64 - 83%,p = 0.46,I² = 0%)。所有报告的不良事件均得到解决。
基于目前的证据,SCI患者中SNM治疗下尿路功能障碍的测试阶段成功率较低,但在永久阶段,SNM的成功率较为乐观。未来,需要设计良好、样本量充足且有足够检验效能的随机对照试验来验证SNM的疗效和安全性。